AMDL, MyGene to broaden Asian focus for human papilloma virus test
This article was originally published in Clinica
Diagnostics firm AMDL has signed an exclusive sublicence with Korean company MyGene International to make the latter's in vitro genotype test for human papilloma virus (HPV) more widely available in the Asian market. The deal will see Tustin, California-based AMDL manufacture, promote, market, distribute and sell the MyGene HPV chip kit in China, Taiwan, Singapore, Malaysia, Thailand, Cambodia and Vietnam.
You may also be interested in...
China's centralized procurement scheme, if further expanded after causing the prices of 32 drugs to be cut by more than half in the latest round, will leave companies no room to breathe easy amid the already devastating coronavirus outbreak, analysts say.
Sangamo licensed Biogen zinc finger protein transcription factor candidates in an alliance worth over $2bn. Exercising an option it gained in 2017, Takeda bought celiac disease-focused PvP Biologics for up to $330m in earn-outs. A strong showing of IPOs prompted biopharma financing to increase from last month.
With many non-CE marked products being allowed onto various EU member state markets, who is going to monitor compliance? TÜV-SÜD’s Bassil Akra calls for cooperation to avoid unsafe products being used on patients.